Results 131 to 140 of about 12,392,515 (266)
Gene mutations and inhibitor formation in patients with hemophilia B
, 1995 The nature of the mutation in the factor IX gene is an important factor in determining whether a patient with hemophilia B will develop an inhibitor. In a series of 62 Swedish families with hemophilia B, including 30 with the severe form, approximately ...
Ljung, R. C R
core +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Accurate laboratory diagnosis is essential for the effective management of bleeding disorders. The World Federation of Hemophilia (WFH) International External Quality Assessment Scheme (IEQAS) provides an international platform for comparative evaluation of laboratory performance.
Silmara de Lima Montalvão +8 more
wiley +1 more source
Concurrent congenital hemophilia B and acquired hemophilia A: a unique case report
Congenital hemophilia B is a rare X-linked recessive bleeding disorder caused by factor IX deficiency. Acquired hemophilia A is a rare, acquired bleeding disorder that presents with new-onset bleeding, especially in older adults, due to the development ...
Cirik, Salih +6 more
core +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht +7 more
wiley +1 more source
Barriers and perceived limitations to early treatment of hemophilia
, 2013 Kapil Saxena Boston Hemophilia Center, Boston Children’s Hospital, Boston, MA, USA Abstract: Early treatment of bleeds in hemophilia patients, both with and without inhibitors, has been shown to be of immense benefit in the overall clinical outcome.
Saxena K
core
Haemophilia, EarlyView.ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno +8 more
wiley +1 more source
Living With Factor VII Deficiency—A Mixed Methods Study
Haemophilia, EarlyView.ABSTRACT Background Factor VII deficiency (FVIID) is a rare autosomal recessive disorder, resulting in potentially unpredictable and life‐threatening bleeding. The prevalence of symptomatic patients is 1 in 300,000. Treatment is mostly given following bleeding, but those with the lowest levels may be offered prophylaxis.
Simon Fletcher +3 more
wiley +1 more source
Artificial Intelligence and Machine Learning in the Context of Hemophilia: A Scope Review
Haemophilia, EarlyView.ABSTRACT Introduction Advances in hemophilia treatment have improved life expectancy, yet challenges remain in disease management, predicting clinical complications, and optimizing healthcare resources. Artificial intelligence (AI) and machine learning (ML) have emerged as promising tools to support clinical decision‐making and personalized care ...
Tatyane Oliveira Rebouças +4 more
wiley +1 more source
Clinical audit of inherited bleeding disorders in a developing country
Indian Journal of Pathology and Microbiology, 2010 Objective: We did a clinical audit to determine the status of coagulation disorders in a hemophilia care center in Pakistan. Setting: Fatimid foundation blood bank and hematological diseases center, Lahore.
Sajid Raihan +4 more
doaj
Haemophilia, EarlyView.ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh +7 more
wiley +1 more source